KRAS and pancreatic neoplasm: Our observation, combined by findings from other groups, corroborates the hypothesis that detection of ctDNA mutated KRAS at diagnosis of advanced pancreatic cancer is correlated with reduced time-to-progression and overall survival (35–37).